# Company Introduction (English Ver)



# Table of Contents

1. Company Overview

Jeisys

- 2. Business Structure
- 3. Products Line Up

## Appendix.



**Company Introduction** 

# 1

# **Company Overview**

01 Corporate Identity02 Company Overview03 History04 Performance



Company Overview

# 01. Corporate Identity

# Jeisys

## A Global Company Specialized for Skincare Aesthetic Medical Devices



based products

• Secure product safety and efficacy (FDA, CE, MFDS, MDSAP)



- 85% of revenue from overseas (1H 2023)
- Establishment of 3 overseas subsidia corporations
- Expanding Global Partnerships

# Excellent

# Business Performances

- CAGR, 56% of revenue (2020~2022)
- 27% of operating profit (1H 2023)

# 02. Company Overview



Company Name	Jeisys Medical Inc.			
Date of Establishment	December 1, 2017 (Before the merger of SPAC: August 25, 2004)			
CEO	Dong Hwan Kang			
Business area	Manufacturing of medical devices			
No. of Employees	228 (As of June-end of 2023)			
Capital	KRW 7,638million (As of June-end 2023)			
Subsidiary	<ul> <li>SACCI Bio Co., Ltd</li> <li>Jeisys Medical Japan Inc.</li> <li>Jeisys Medical Australia Pty. Ltd.</li> <li>Jeisys Medical VN Company Ltd.</li> </ul>			
Head office	307, 308, 401, 808, 1015, 96, Gamasan-ro, Geumcheon- gu, Seoul, Republic of Korea			
Homepage	http://www.jeisys.com			






Name	Official responsibilities			
Myung Hoon Kim	COO			
Tae Hwan Kim	CFO			
Min Young Kim	Director of Product Development			
Hiroyuki Matsuda	Jeisys Medical Japan, Inc. CEO			

## 03. History

## Jeisys



Entrance of foreign Aesthetic medical devices into domestic market ·Technology development and advancement of procedures by


domestic companies

 $\cdot$  Secure efficacy and safety certified by FDA, CE, MDSAP, etc.

Accelerate global market penetration by securing product competency

# 04. Performance

## Jeisys



**Company Introduction** 

# 2

# **Business Structure**

01 Integrated Business Process
02 Excellent R&D Capability
03 In-house Production System
04 Expansion of B2C Marketing Activities
05 Establishment of Domestic and Overseas Sales Network
06 Overseas business capabilities




#### **Business Structure**

## **01. Integrated Business Process**

## Jeisys

#### Establishment of end-to-end process including product planning, development, production etc.



# 02. Excellent R&D Capability




#### Establish R&D capability by organizing research-centric organization

#### Research center

#### R&D personnel over 30% of total company employees

licensing	R&D	New product	Product strategy
9	40	14	8

R&D Cost Trend



#### Intellectual Properties

Division	No.	Details	
Patent	213	Proprietary technologies developed in-house whic are applied to the products	
Design	8	Product designs, etc.	
Trademark	118	Trademarks of the products, etc	

#### Domestic and overseas certificates (major countries)

Country	No. certified items
Korea (MFDS)	186
Europe (CE)	3
USA (FDA)	21
Brazil (Anvisa)	6
Canada (MDL)	3
Japan (PMDA)	4
Australia (ARTG)	5
China (NMPA)	5
Total	233

# 03. In-house Production System

## Jeisys

#### Secure cost and quality competitiveness by production process enhancement

#### SCM

#### • MRP calculation

• Order and purchase raw materials




### Production

#### Factory

Daerung Technotown8, 96, Gamasan-ro,

Geumcheon-gu, Seoul, Korea


Production Unit : EA capability(Device) 3,968 2,812 2,293 1,655 1,659 2020 2021 2022 1H2023 2019 **Output(Device)** Unit : EA 3,420 2.376 1,605 1,467 1.374 1H2023 2019 2020 2021 2022



# 04. Expansion of B2C Marketing Activities

# Jeisys

#### **Online-based B2C marketing expansion**



Customers have started demonstrating brand preference since the information on the Aesthetic medical devices are now widely available due to the development of social media Hospitals & clinics reach out to us upon consumers' brand preference Traditional importance (hospitals and doctors) + enhanced importance of marketing to consumers by manufacturers Brand **SNS** Community Banners Youtube searching

# 05. Establishment of Domestic and Overseas Sales Network

85%

# Jeisys

### Expand domestic and overseas sales network by implementing customized sales strategies

#### **Overseas**

#### ✓ Overseas subsidiaries

- Secure inhouse sales reps
- Sales to hospitals and distributors

#### ✓ Other territories in overseas

- · Establish sales strategies by continent
- Develop new buyers dispatching sales reps from HQ
- Offline: Events such as workshops inviting local doctors
- · Online: web seminars
- Develop emerging markets: India, Vietnam, and Latin America

#### ✓ Status of network by continent

Asia	Europe	Middle East	North America	Others	Total
16	18	16	12	8	70

#### Domestic


#### Establish customized sales strategies ✓ Offline by product group • Sales by direct reps and distributors - Seoul and metropolitan areas, Youngdong, Jeju : Direct sales - Other regions: Distributors • Enhance sales efficiency providing by demonstration device • Establish efficient network using key doctors - Secure 35 KOLs including dermatologists Sales in 1H 2023 KRW 64.3billion 15% Onlines (Consolidated) • Operate Jeisys Mall (mall.jeisys.com) Sales of consumables Jeisys MINAS (INNE) (INNE) (INNE) (INNE) (INNE) Actor (INNE) (INNE) (INNE) (INNE) CELLECV. AL2/8594 1544-1639

**Business Structure** 

# 06. Overseas business capabilities

## Jeisys

Entering to more than 60 countries and the export growth was 60.6% in the last 3 years Continue expanding the export share centered in Japan and North America (1H2023 85%)





**Company Introduction** 

# 3

# **Products Line Up**


01 Product Portfolio
02 Key Product\_RF(POTENZA)
03 Key Product\_RF(Density)
04 Key Product\_HIFU(LinearZ)
05 Key Product\_ Solution Delivery(D'Liv)



### Products Line Up 01. Product Portfolio

# Jeisys

#### Diverse portfolio that meets consumer demands



#### Products Line Up

# 02. Key Product\_RF(POTENZA)

# Jeisys



#### Overview

• 3 Handpieces and 14 tips to treat diverse indications with less pain

Technology to deliver solutions
 using RF microneedling

Optimal parameters using Bi/Mono/1Mhz/2Mhz combinations

#### Features

· Real-time impedance monitoring

• 4 modes using RF Customization

 Drug Delivery – Pumping Tips (CP-tip)

 Interchangeable Monopolar & Bipolar continuous output technology

#### Indication

- Melasma
- Rosacea
- Skin Tightening
- Scar, Acne Scar

# POTENZA

**POWER** of recovery

**POTENTIAL** to evolve

**POSSIBILITY** to overcome limitations

Products Line Up

# 02. Key Product\_RF(POTENZA)\_Tip



✓ Non-Invasive	Non-Invasive Tips		✓ Invasive Tip	S		
DIAMOND	DDR	SFA	Insulated	Non- Insulated	Pumping	1-Pin
DIAMOND	DDR	SFA	I-16 I-25 I-49	N-16 N-25 N-49	CP-16 CP-25	P1-08 A1-12 A1-15
Lifting & Tightening	Rejuvenation	Fine line, Skin Textures	Wrinkle, Rejuvenation	Melanin, Flushing, Pore	Drug Delivery, Scar	Acnes

### Products Line Up 03. Key Product\_RF(Density)

# Jeisys



Overview	• A device that generates collagen by monopolar RF energy reaching down to the deep dermis while achieving tightening effects through bipolar RF energy affecting the epidermal to upper dermal layer.
Features	<ul> <li>Reduces pain and prevents burn by cooling skin through spraying coolant</li> <li>World's first bipolar indirect heating</li> <li>Monopolar and Bipolar Sequential Pulse</li> <li>Single &amp; Multi MHz</li> </ul>
Indication	• Wrinkle improvement • Skin Tightening • Lifting

### Products Line Up 03. Key Product\_RF(Density)\_Tip



✓ Facial type		✓ Body type
EYE TIP	FULL FACE TIP	BODY TIP
<ul><li>Wrinkles</li><li>Eyebrow lifting</li></ul>	<ul><li>Tightening</li><li>Lifting</li></ul>	<ul> <li>Double chin</li> <li>Abdomen</li> <li>Arm</li> <li>Axilla</li> <li>Body contouring</li> </ul>

### Products Line Up 04. Key Product\_HIFU(LinearZ)

## Jeisys



#### Overview

• A product that features the function to control various depths in a single cartridge and two modes (dot and linear) to be used selectively has been designed for the convenience and safety of the user.

#### Features

 Able to control Depth & Mode in one cartridge

Convenient treatment thanks to the DWR(Degassed Water Replacement)

 62% faster than previous model (100 shots 60s->37s)

• Safety secured through Z-patten energy irradiation(=overlap of irradiation at each end avoided)

Effective clinical parameters secured through fat proliferation and reduction and tightening

#### Indication

- Tightening and lifting
- Double chin improvement
- Fat reduction


## Products Line Up 04. Key Product\_HIFU(LinearZ)\_Cartridge



	✓ Facial type			✓ Body type
	A(Basic)	B(Essential)	C(Core)	D(Contour)
Mode	LinearZ	LinearZ	LinearZ	LinearZ
<ul> <li>1. Dot</li> <li>2. Linear</li> <li>*Two modes available in all cartridges</li> </ul>	<ul> <li>2.0 mm DOT</li> <li>2.0 mm LINEAR</li> <li>3.0 mm DOT</li> <li>3.0 mm LINEAR</li> </ul>	<ul> <li>1.5 mm DOT</li> <li>1.5 mm LINEAR</li> <li>2.0 mm DOT</li> <li>2.0 mm LINEAR</li> <li>3.0 mm DOT</li> <li>3.0 mm LINEAR</li> </ul>	• 4.5 mm DOT • 4.5 mm LINEAR	<ul> <li>9.0 mm DOT</li> <li>9.0 mm LINEAR</li> <li>11.0 mm DOT</li> <li>11.0 mm LINEAR</li> <li>13.0 mm DOT</li> <li>13.0 mm LINEAR</li> </ul>



#### Effective solution delivery through micro-needling injector mode without energy




Jeisys

Products Line Up

# 05. Key Product\_Solution Delivery(D'Liv)\_Tip

# Jeisys





Company Introduction

# **APPENDIX**

01 Governance02 Financial Information



# **O1. Governance**

# Jeisys

#### Shareholders

Rating Classification	Shareholder Name	Number of Shares	Stake Percentile
Largest Shareholders	Dong Hwan Kang	17,972,844	23.53%
	Myung Hoon Lee	3,739,127	4.90%
	Tae Hwan Kim	294,425	0.39%
Affiliated Persons	Min Young Kim	270,907	0.35%
Annialed Persons	Hye Jin Sun 141,810		0.19%
	YI WON JU	115,580	0.15%
	ll Kwon Kang	2,000	0.00%
Treasury Shares	Jeisys Medical Inc	645,539	0.84%
Holding at least 5%	The Capital Group Companies, Inc.	5,703,950	7.47%
Other shareholders	_	47,498,316	62.18%
Issued Shares	-	76,384,498	100.00%

Note1) As of June-end 2023

#### Board of directors

Classification	Name	In-House Position
Chairman (In-house director)	Dong Hwan Kang	CEO
In-house director	Myung Hoon Kim	COO
In-house director	Tae Hwan Kim	CFO
In-house director	Min young Kim	Director of Product Development
Outside director	Ji Hyung Lee	-
Outside director	Se Woon Choi	_
Outside director	Sung Wook Jang	-

#### Audit Committee

Classification	Name	In-House Position
Chairman	Ji Hyung Lee	-
Member	Se Woon Choi	-
Member	Sung Wook Jang	-

#### APPENDIX

# 02. Financial Information



#### Consolidated Statements of Financial Position

2021	2022	1H2023
54,173	74,483	89,988
19,886	43,634	43,646
74,059	118,117	133,634
24,027	26,583	27,026
2,379	11,579	11,022
26,405	38,162	38,048
7,130	7,130	7,638
26,849	26,421	33,717
6,367	12,434	7,685
-126	-562	-917
6,865	33,995	46,879
568	537	584
47,654	79,954	95,586
	54,173 19,886 <b>74,059</b> 24,027 2,379 <b>26,405</b> 7,130 26,849 6,367 -126 6,865 568	54,173       74,483         19,886       43,634         19,886       43,634         74,059       118,117         24,027       26,583         2,379       11,579         26,405       38,162         7,130       7,130         26,849       26,421         6,367       12,434         -126       -562         6,865       33,995         568       537

Unit: KRW million

Note1) Consolidated based on K-IFRS

#### Consolidated Statements of Income

Unit: KRW million

			Unit: KRW million
field	2021	2022	1H2023
Sales	81,296	116,550	64,266
COGS	24,649	36,975	20,072
Gross Profit	56,647	79,575	44,194
SG&A	33,042	45,540	26,932
Operating Profit	23,604	34,035	17,262
Finance Income	1,045	2,097	1,451
Finance Costs	897	1,983	2,283
Other Gains	208	100	9
Other Losses	10,866	362	69
Profit before tax	13,093	33,886	16,452
Income tax	-667	6,873	3,521
Profit from discontinued operations	-268	-	-
Net Profit	13,493	27,012	12,930

